Literature DB >> 18032940

Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy.

Jim Todd1, Judith R Glynn, Milly Marston, Tom Lutalo, Sam Biraro, Wambura Mwita, Vinai Suriyanon, Ram Rangsin, Kenrad E Nelson, Pam Sonnenberg, Dan Fitzgerald, Etienne Karita, Basia Zaba.   

Abstract

OBJECTIVES: To estimate survival patterns after HIV infection in adults in low and middle-income countries.
DESIGN: An analysis of pooled data from eight different studies in six countries.
METHODS: HIV seroconverters were included from eight studies (three population-based, two occupational, and three clinic cohorts) if they were at least 15 years of age, and had no more than 4 years between the last HIV-negative and subsequent HIV-positive test. Four strata were defined: East African cohorts; South African miners cohort; Thai cohorts; Haitian clinic cohort. Kaplan-Meier functions were used to estimate survival patterns, and Weibull distributions were used to model and extend survival estimates. Analyses examined the effect of site, age, and sex on survival.
RESULTS: From 3823 eligible seroconverters, 1079 deaths were observed in 19 671 person-years of follow-up. Survival times varied by age and by study site. Adjusting to age 25-29 years at seroconversion, the median survival was longer in South African miners: 11.6 years [95% confidence interval (CI) 9.8-13.7] and East African cohorts: 11.1 years (95% CI 8.7-14.2) than in Haiti: 8.3 years (95% CI 3.2-21.4) and Thailand: 7.5 years (95% CI 5.4-10.4). Survival was similar for men and women, after adjustment for age at seroconversion and site.
CONCLUSION: Without antiretroviral therapy, overall survival after HIV infection in African cohorts was similar to survival in high-income countries, with a similar pattern of faster progression at older ages at seroconversion. Survival appears to be significantly worse in Thailand where other, unmeasured factors may affect progression.

Entities:  

Mesh:

Year:  2007        PMID: 18032940      PMCID: PMC5784803          DOI: 10.1097/01.aids.0000299411.75269.e8

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women.

Authors:  C Costello; J Tang; C Rivers; E Karita; J Meizen-Derr; S Allen; R A Kaslow
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  The natural history of HIV-1 infection in Africa.

Authors:  D Morgan; J Whitworth
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

3.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Authors:  Dilys Morgan; Cedric Mahe; Billy Mayanja; J Martin Okongo; Rosemary Lubega; James A G Whitworth
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

4.  Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.

Authors:  T R Sterling; D Vlahov; J Astemborski; D R Hoover; J B Margolick; T C Quinn
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  HIV infection in Haiti: natural history and disease progression.

Authors:  M M Deschamps; D W Fitzgerald; J W Pape; W D Johnson
Journal:  AIDS       Date:  2000-11-10       Impact factor: 4.177

6.  Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe?

Authors:  M Prins; R P Brettle; J R Robertson; I Hernández Aguado; B Broers; N Carré; D J Goldberg; R Zangerle; R A Coutinho; A van den Hoek
Journal:  Int J Epidemiol       Date:  1999-06       Impact factor: 7.196

7.  The impact of HIV/AIDS on mortality and household mobility in rural Tanzania.

Authors:  M Urassa; J T Boerma; R Isingo; J Ngalula; J Ng'weshemi; G Mwaluko; B Zaba
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

8.  HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort.

Authors:  D W Mulder; A J Nunn; H U Wagner; A Kamali; J F Kengeya-Kayondo
Journal:  AIDS       Date:  1994-01       Impact factor: 4.177

9.  Four years of natural history of HIV-1 infection in african women: a prospective cohort study in Kigali (Rwanda), 1988-1993.

Authors:  V Leroy; P Msellati; P Lepage; J Batungwanayo; D G Hitimana; H Taelman; J Bogaerts; F Boineau; P Van de Perre; A Simonon
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-08-01

10.  The relationship between HIV seroconversion illness, HIV test interval and time to AIDS in a seroconverter cohort.

Authors:  F Tyrer; A S Walker; J Gillett; K Porter
Journal:  Epidemiol Infect       Date:  2003-12       Impact factor: 2.451

View more
  87 in total

1.  The Age Pattern of Increases in Mortality Affected by HIV: Bayesian Fit of the Heligman-Pollard Model to Data from the Agincourt HDSS Field Site in Rural Northeast South Africa.

Authors:  David J Sharrow; Samuel J Clark; Mark A Collinson; Kathleen Kahn; Stephen M Tollman
Journal:  Demogr Res       Date:  2013-12-03

2.  CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.

Authors:  Albert K Minga; Charlotte Lewden; Delphine Gabillard; Germain I Bomisso; Thomas-d'aquin Toni; Arlette A Emième; Vincent Yapo; André Inwoley; Roger Salamon; Xavier Anglaret
Journal:  AIDS       Date:  2011-03-27       Impact factor: 4.177

3.  Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings.

Authors:  April D Kimmel; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman
Journal:  Med Decis Making       Date:  2014-10-20       Impact factor: 2.583

4.  A missing piece in the puzzle: HIV in mature adults in sub-Saharan Africa.

Authors:  Portia C Mutevedzi; Marie-Louise Newell
Journal:  Future Virol       Date:  2011-06       Impact factor: 1.831

5.  Coreceptor usage, diversity, and divergence in drug-naive and drug-exposed individuals from Malawi, infected with HIV-1 subtype C for more than 20 years.

Authors:  Ishla Seager; Simon A Travers; Michael D Leeson; Amelia C Crampin; Neil French; Judith R Glynn; Grace P McCormack
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

6.  A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008.

Authors:  Thomas M Rehle; Timothy B Hallett; Olive Shisana; Victoria Pillay-van Wyk; Khangelani Zuma; Henri Carrara; Sean Jooste
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

7.  HIV mortality and infection in India: estimates from nationally representative mortality survey of 1.1 million homes.

Authors:  Prabhat Jha; Rajesh Kumar; Ajay Khera; Madhulekha Bhattacharya; Paul Arora; Vendhan Gajalakshmi; Prakash Bhatia; Derek Kam; Diego G Bassani; Ashleigh Sullivan; Wilson Suraweera; Catherine McLaughlin; Neeraj Dhingra; Nico Nagelkerke
Journal:  BMJ       Date:  2010-02-23

8.  HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985-2008.

Authors:  Zhihui Dou; Ray Y Chen; Zhe Wang; Guoping Ji; Guoping Peng; Xiaochun Qiao; Jihua Fu; Xiangdong Meng; Marc Bulterys; Ye Ma; Yan Zhao; Ning Wang; Fujie Zhang
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age.

Authors:  Timothy B Hallett; Peter Ghys; Till Bärnighausen; Ping Yan; Geoff P Garnett
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Authors:  Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.